Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer.
Cancers (Basel). 2023 Feb 11;15(4):1168. doi: 10.3390/cancers15041168.
Cancers (Basel). 2023.
PMID: 36831511
Free PMC article.
Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers.
Kuchukulla RR, Hwang I, Park SW, Moon S, Kim SH, Kim S, Chung HW, Ji MJ, Park HM, Kong G, Hur W.
Kuchukulla RR, et al.
Pharmaceuticals (Basel). 2022 Aug 23;15(9):1041. doi: 10.3390/ph15091041.
Pharmaceuticals (Basel). 2022.
PMID: 36145262
Free PMC article.
Item in Clipboard
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ, Jin S, Cho H, Won HY, An HW, Jeong GY, Park YU, Kim HY, Park MK, Son T, Min KW, Jang KS, Oh YH, Lee JY, Kong G.
Choi HJ, et al.
EMBO Rep. 2019 Oct 4;20(10):e48058. doi: 10.15252/embr.201948058. Epub 2019 Aug 30.
EMBO Rep. 2019.
PMID: 31468695
Free PMC article.
Item in Clipboard
Cite
Cite